NCT01286987 - Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

January 3, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

January 30, 2017

Conditions

Advanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, EpithelialEwing SarcomaSmall Cell Lung CarcinomaProstate CancerPancreas Cancer

Interventions

DRUG

Talazoparib

Oral capsule with multiple dosage forms given once daily

Trial Locations (15)

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

Investigational Drug Services, Indianapolis

IU Health University Hospital, Indianapolis

IU Health Bloomington Hospital, Bloomington

University of Michigan Health System, Ann Arbor

Scottsdale Healthcare, Scottsdale

Virginia G. Piper Cancer Center Research Pharmacy, Scottsdale

(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles

Ronald Reagan UCLA Medical Center, Los Angeles

UCLA Hematology/Oncology, Los Angeles

Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles

Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica

UCLA Hematology/Oncology - Santa Monica, Santa Monica

The University of Texas MD Anderson Cancer Center, Houston

Royal Marsden Hospital NHS Foundation Trust, Sutton